(VIANEWS) - Shares of ARGENX SE (BEL 20: ARGX.BR) jumped by a staggering 26.11% to €421.20 at 11:08 EST on Monday, following the last session's upward trend. BEL 20 is jumping 3.26% to €3,679.41, after two sequential sessions in a row of losses. This seems, so far, a very positive trend exchanging session today.
About ARGENX SE
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ARGENX SE has a trailing twelve months EPS of €-8.02.
Volume
Today's last reported volume for ARGENX SE is 68977 which is 26.36% above its average volume of 54585.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ARGENX SE's stock is considered to be overbought (>=80).
Volatility
ARGENX SE's last week, last month's, and last quarter's current intraday variation average was a negative 1.30%, a negative 0.40%, and a positive 1.25%.
ARGENX SE's highest amplitude of average volatility was 1.50% (last week), 1.19% (last month), and 1.25% (last quarter).
More news about ARGENX SE (ARGX.BR).